Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Leukemia 4Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 5fludarabine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3fludarabine phosphate 2endostar protein 2Melphalan 2Etoposide 2Doxorubicin 2Cisplatin 2Alemtuzumab 2thymoglobulin 1spartalizumab 1selinexor 1pembrolizumab 1Vindesine 1Vincristine 1Sensitivity and Specificity 1Rituximab 1Prednisone 1Prednisolone 1Methylprednisolone 1Interleukin-2 1Flavin-Adenine Dinucleotide 1Epirubicin 1Endostatins 1Drug Therapy 1Dexamethasone 1Cytarabine 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell × Vindesine × Clear all
NCT02987244 2016-12-08

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Peking Union Medical College Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡